aiwiki.page
English
Health / Medicine & Treatment / targeted-cancer-therapy

Targeted Cancer Therapy

Targeted cancer therapy treats malignancies by interfering with specific molecular dependencies or delivering treatment through selected tumor-associated targets.

45 keywords19 linked from6 not yet writtenWritten by AI
CancerPrecision Medici…ChemotherapyRadiation Therap…SurgeryCancer Immunothe…Breast cancerProstate cancerTargeted C…

Targeted cancer therapy is the treatment of cancer with agents directed at particular molecules, signaling pathways, or biological dependencies that support malignant growth and survival. These treatments can inhibit abnormal proteins, block growth signals, alter the tumor’s supporting environment, or deliver a toxic payload to cells bearing a selected surface marker. Their defining feature is a specified molecular target or dependency, rather than complete specificity for cancer cells. Many targets also occur in healthy tissues, and targeted treatments can cause substantial adverse effects.

The field connects molecular cancer biology with precision medicine. In some diseases, a particular genetic alteration identifies both the cause of abnormal signaling and a highly effective treatment. In others, target expression, tissue context, interacting pathways, and acquired resistance make the relationship less straightforward. Targeted therapy includes established treatments for blood cancers and solid tumors, used alone or alongside chemotherapy, radiotherapy, surgery, and immune-based treatments.

The boundaries of the term are not absolute. Hormone-directed treatments are among its earliest examples, while some tumor-targeting antibodies are also classified as cancer immunotherapy. Contemporary practice commonly distinguishes molecularly targeted drugs from conventional cytotoxic chemotherapy and immune-checkpoint blockade, while recognizing substantial overlap among their mechanisms.

Historical development and scope

The biological logic of targeted treatment predates modern molecular genetics. In 1896, George Beatson reported regression of advanced breast cancer after removal of the ovaries, providing early evidence that a malignancy could depend on a physiological signal produced elsewhere in the body. Later work established the importance of estrogen signaling in many breast cancers. Tamoxifen and aromatase inhibitors subsequently made endocrine treatment a major component of breast cancer care. Treatments that suppress androgen production or androgen-receptor activity established a corresponding approach in prostate cancer. Although often discussed separately from newer targeted drugs, these treatments operate through identifiable molecular dependencies.

The discovery of recurrent chromosome abnormalities helped connect cancer to specific molecular lesions. In 1960, Peter Nowell and David Hungerford described the unusually small chromosome later called the Philadelphia chromosome. Janet Rowley demonstrated in 1973 that it resulted from a translocation between chromosomes 9 and 22. Subsequent research identified the BCR::ABL1 fusion, whose protein product has continuously active tyrosine kinase activity. This provided a particularly clear causal chain from chromosome rearrangement to abnormal enzyme activity and malignant cell growth in chronic myeloid leukemia.

Imatinib, approved in the United States in 2001 for Philadelphia chromosome–positive chronic myeloid leukemia, became a landmark example of treatment directed at a cancer-driving protein. Its development involved biochemical studies of kinase inhibition, preclinical investigation, and clinical trials associated with researchers including Nicholas Lydon, Brian Druker, and Charles Sawyers. Imatinib also inhibits KIT and PDGF receptors, enabling its use in other molecularly defined diseases, notably many gastrointestinal stromal tumors. Its history illustrates both the power of a well-chosen target and the fact that a successful targeted drug need not bind only one protein.

Antibody technology developed along a complementary path. Georges Köhler and César Milstein described the hybridoma method for producing monoclonal antibodies in 1975. Rituximab, directed against CD20, received United States approval in 1997 for certain B-cell lymphomas, followed by trastuzumab for HER2-positive breast cancer in 1998. These treatments demonstrated that cell-surface proteins could serve as clinically useful targets even when the antibody’s effects involved several mechanisms, including immune-mediated killing.

The subsequent expansion of the field has involved EGFR, ALK, BRAF, BTK, PARP, and numerous other targets. Nevertheless, “targeted” does not mean universally effective, curative, or less toxic. It describes a treatment’s molecular rationale. Whether that rationale translates into clinical benefit depends on disease context, drug properties, appropriate patient selection, and evidence from treatment studies.

Molecular dependencies and mechanisms of action

Cancer develops through accumulated changes in DNA, gene expression, cellular regulation, and interactions with surrounding tissues. Some changes directly promote malignant behavior; others accompany tumor evolution without being essential to it. A cancer-driving oncogene may encode an overactive signaling protein, while loss of a tumor-suppressing function can remove restraints on proliferation or survival. Targeted therapy is most effective when its target represents a dependency that malignant cells cannot easily bypass.

One important dependency is often called oncogene addiction: despite possessing many abnormalities, a tumor may remain strongly dependent on one dominant signaling system. BCR::ABL1-positive leukemia and some EGFR-mutant lung cancers exemplify this principle. Inhibiting the dominant driver can interrupt several downstream survival and proliferation signals at once. However, the presence of a mutation is not sufficient by itself to establish dependence. The precise variant, its functional consequences, the tissue in which it occurs, and additional molecular alterations all influence drug sensitivity.

Many drugs target protein kinases, enzymes that transfer phosphate groups to other molecules. Receptor kinases such as EGFR and HER2 transmit signals from the cell surface, while intracellular kinases such as ABL, BRAF, and BTK participate in signaling networks inside the cell. These networks include the RAS–RAF–MEK–ERK and PI3K–AKT–mTOR pathways, which regulate growth, metabolism, and survival. A protein kinase inhibitor can occupy the ATP-binding region, bind another regulatory site, or form a covalent bond with a particular amino-acid residue. Differences in binding mode influence selectivity and vulnerability to resistance mutations.

Other treatments exploit defects in DNA repair. Synthetic lethality describes a relationship in which disruption of either of two functions alone is compatible with survival, but their combined disruption is lethal. PARP inhibitors exploit repair vulnerabilities in some tumors with defective homologous recombination, including cancers with certain BRCA1 or BRCA2 alterations. PARP inhibition and trapping of PARP on DNA create lesions and replication stress that these cells may be poorly equipped to resolve. The relationship is more complex than a simple requirement for a BRCA mutation, because repair function can be lost or restored through several mechanisms.

Targets can also lie outside the malignant cell. Inhibiting angiogenesis, the formation of new blood vessels, can restrict vascular support for tumor growth. Bevacizumab binds vascular endothelial growth factor A, whereas several small molecules inhibit vascular growth-factor receptors. Other therapies target survival proteins such as BCL2 or cell-cycle regulators such as CDK4 and CDK6. These mechanisms show why molecular targeting encompasses more than blocking a mutated growth receptor: it can exploit altered survival thresholds, tissue support, or dependencies created by loss of normal cellular functions.

Drug platforms and delivery strategies

Small-molecule drugs constitute a large part of targeted cancer therapy. Many can cross the cell membrane and reach intracellular proteins, making them suitable for kinase inhibition, interference with DNA repair, or disruption of protein interactions. Most are taken orally, although route of administration is not what defines the class. Their relatively small size permits access to binding pockets that antibodies cannot usually reach. Conversely, activity against related proteins can produce unintended pharmacological effects, and drug exposure may vary with absorption, metabolism, transport, and interactions with other medicines.

Monoclonal antibodies usually recognize extracellular targets, such as a receptor on a cell surface or a soluble signaling molecule. Trastuzumab binds HER2, while cetuximab and panitumumab bind EGFR. Their effects can include receptor blockade, altered receptor trafficking, and recruitment of immune effector mechanisms. Rituximab recognizes CD20 on B cells and can promote cell killing through several pathways. Thus, an antibody may be molecularly targeted while depending partly on the immune system to produce its therapeutic effect.

An antibody–drug conjugate combines an antibody, a chemical linker, and a potent cytotoxic payload. After binding its antigen, the conjugate is often internalized, allowing intracellular processing to release the drug. Ado-trastuzumab emtansine and trastuzumab deruxtecan use HER2-directed antibodies but carry different payloads and linkers, giving them distinct pharmacological and clinical properties. Depending on payload permeability and release mechanisms, nearby cells with lower target expression may also be affected. This “bystander effect” can help address heterogeneous antigen expression, but delivery is not confined perfectly to malignant tissue.

Other platforms broaden the concept of targeting. A bispecific antibody recognizes two different molecular features; some connect a tumor-associated antigen with CD3 on T cells, bringing immune cells into close contact with malignant cells. These agents are commonly classified as immunotherapies as well as targeted biologics. Radioligand therapies couple a targeting molecule to a radioactive isotope. Lutetium-177–labeled agents directed at somatostatin receptors or prostate-specific membrane antigen illustrate how a selected binding target can deliver radiation rather than inhibit the target’s normal biochemical function.

Targeted protein degradation provides another strategy. Instead of merely blocking a protein’s activity, a drug can promote its removal by the cell’s protein-disposal machinery. Immunomodulatory drugs used in multiple myeloma alter the substrate specificity of cereblon-containing ubiquitin ligase complexes, leading to degradation of particular regulatory proteins. Bifunctional degraders use a related principle by bringing a target protein and an E3 ubiquitin ligase together. Across these platforms, target recognition, tissue distribution, payload action, and clearance are separate determinants of effectiveness; strong molecular binding alone does not guarantee a useful medicine.

Biomarkers and selection of treatment

A biomarker is a measurable characteristic that provides information about a biological process or disease. In targeted therapy, a predictive biomarker identifies a group more likely to benefit from a particular treatment, while a prognostic biomarker provides information about disease outcome independently of that treatment. The distinction is important: an alteration associated with aggressive cancer does not necessarily indicate sensitivity to a drug directed against it. A clinically useful predictive marker requires evidence linking a defined test result to a treatment effect.

Testing methods measure different kinds of information. Immunohistochemistry detects proteins within tissue and is central to assessing hormone receptors and HER2 in breast cancer. In situ hybridization can reveal gene amplification or rearrangement. Polymerase chain reaction detects selected DNA or RNA sequences, while next-generation sequencing can examine many genes simultaneously. RNA-based methods are particularly useful for some gene fusions. These techniques are not interchangeable: a protein-expression assay, a DNA sequence result, and a functional measure of pathway activity may answer different clinical questions.

Tumor material commonly comes from a biopsy or surgical specimen. Its interpretation depends on histopathology, the proportion of malignant cells, specimen preservation, assay coverage, and the ability to detect the relevant alteration. HER2 amplification or overexpression, activating EGFR mutations, ALK rearrangements, and selected BRCA alterations illustrate distinct biomarker categories. A companion diagnostic is a test linked to the safe and effective use of a particular therapeutic product. Its required specimen, scoring criteria, and threshold are specific to the drug and indication rather than universal properties of the target.

A liquid biopsy analyzes tumor-derived material in bodily fluids, most commonly circulating tumor DNA in blood. It can identify actionable alterations when tissue is limited and can reveal resistance-associated changes during treatment. Its limitations are biological as well as technical. Some tumors shed little DNA into the circulation, especially when disease burden is low or largely confined to certain anatomical sites. A negative blood result therefore does not necessarily establish that an alteration is absent. In addition, age-related clonal changes in blood-forming cells can contribute variants that are not derived from the solid tumor.

The meaning of an alteration also depends on context. Activating RAS mutations predict a lack of benefit from conventional EGFR-antibody strategies in relevant colorectal cancer settings, even though EGFR itself may be present. Different variants within one gene can confer sensitivity, resistance, or uncertain significance. Molecular findings can also change over time under treatment pressure. Consequently, an “actionable” result is not simply an abnormal gene: it is a specific finding supported by a defined relationship among tumor type, variant, drug, treatment setting, and clinical evidence.

Clinical applications across cancer types

Blood cancers have supplied some of the clearest examples of successful molecular targeting. In chronic myeloid leukemia, BCR::ABL1 inhibitors can achieve sustained suppression of the malignant clone, monitored through standardized molecular measurements of fusion-gene transcripts. Later-generation inhibitors provide alternatives for particular resistance patterns or treatment settings. In B-cell malignancies, BTK inhibitors interfere with signaling important to malignant-cell survival and interactions with the tissue environment. Venetoclax inhibits BCL2 and is used in defined settings in chronic lymphocytic leukemia and acute myeloid leukemia, often in combinations.

In breast cancer, different biological subtypes require different approaches. Estrogen-receptor-positive disease can be treated through interference with estrogen production or receptor activity. CDK4/6 inhibitors suppress cell-cycle progression and have established roles alongside endocrine therapy in specified settings. HER2-directed antibodies, kinase inhibitors, and antibody–drug conjugates address tumors defined by HER2 amplification, overexpression, or particular expression categories. These groups cannot be treated as interchangeable: eligibility and expected benefit depend on the agent, assay result, disease stage, and prior therapy.

Lung cancer, particularly nonsmall-cell lung cancer, illustrates the increasing subdivision of a conventional diagnosis into molecular groups. Targetable alterations include selected changes involving EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, and KRAS. Different drugs recognize different abnormal proteins or variants. Osimertinib, for example, targets sensitizing EGFR mutations and the T790M resistance alteration, while selected KRAS inhibitors bind the G12C mutant protein. Intracranial drug activity is important because brain metastases are common in several molecular subtypes; activity against systemic disease does not automatically imply effective control within the brain.

Tissue context remains decisive in solid tumors. BRAF V600 inhibition can produce substantial responses in melanoma, especially with combined BRAF and MEK blockade, but BRAF inhibition alone has limited activity in colorectal cancer because feedback signaling through EGFR can restore pathway activity. Combining BRAF-directed treatment with EGFR blockade addresses this mechanism in defined colorectal cancer settings. Gastrointestinal stromal tumors provide another example: KIT and PDGFRA alterations can guide treatment, but individual variants differ markedly in sensitivity to particular inhibitors.

Some therapies are classified by a molecular feature across multiple primary sites. Larotrectinib and entrectinib received United States approvals in 2018 and 2019, respectively, for specified advanced solid tumors with NTRK gene fusions. Such tissue-agnostic indications do not imply identical evidence or outcomes in every cancer type. Moreover, targeted therapy is no longer confined to widespread disease. Trastuzumab in HER2-positive early breast cancer, imatinib after resection of selected high-risk gastrointestinal stromal tumors, and osimertinib after surgery for eligible EGFR-mutant lung cancer demonstrate its use in reducing recurrence risk as well as controlling established metastatic disease.

Primary resistance, acquired resistance, and tumor evolution

Resistance may be present before treatment or emerge after an initial response. Primary resistance can reflect an incorrectly identified dependency, a variant that the drug does not inhibit, insufficient exposure, or an alternative pathway that already sustains survival. Acquired resistance arises when treatment changes the relative survival of different cell populations. Resistant cells may have existed at low frequency before therapy or may acquire relevant changes during the course of disease. Drug exposure acts as a selective pressure rather than necessarily creating a specific resistance mutation.

Changes in the target itself are a major mechanism. A substitution near a drug-binding region may reduce inhibitor binding while preserving the protein’s cancer-promoting activity. The ABL T315I alteration is a well-known example in chronic myeloid leukemia. In EGFR-mutant lung cancer, T790M was a common resistance mechanism after earlier-generation EGFR inhibitors; osimertinib was developed to inhibit it as well as common sensitizing EGFR variants. Resistance to osimertinib can then involve other changes, including EGFR C797S in some tumors. Each successive drug therefore creates a different landscape of possible escape routes.

Tumors can also bypass a blocked target. Amplification of MET, activation of downstream signaling, or use of an alternative receptor can restore survival signals despite continued inhibition of the original driver. DNA-repair-directed treatment has its own escape mechanisms: secondary changes can restore the reading frame and some function of BRCA genes, reducing sensitivity to PARP inhibitors. Reduced drug accumulation, increased export, altered cell-death regulation, and changes in antigen expression can contribute to resistance across other drug classes.

Resistance need not be explained by a new DNA mutation. Cancer cells can change their transcriptional state, differentiation program, metabolism, or interaction with surrounding cells. Some EGFR-mutant lung adenocarcinomas undergo transformation to small-cell lung cancer during treatment. Slow-cycling drug-tolerant cell populations may survive initial exposure and later contribute to relapse. Spatial heterogeneity further complicates interpretation: different metastases can contain different resistant subclones, so one biopsy may not represent the entire disease.

Combination treatment can suppress complementary escape routes, but its rationale must be supported by clinical evidence and acceptable toxicity. BRAF–MEK combinations, endocrine therapy with CDK4/6 inhibition, and selected regimens that combine targeted drugs with chemotherapy illustrate established approaches. In certain diseases, local treatment of a small number of progressing lesions is studied or used alongside continued systemic therapy, reflecting the possibility of regionally restricted resistance. The sequence of treatments also matters: an alteration selected by one drug may create sensitivity to another, while some resistance mechanisms confer cross-resistance. These relationships make cancer evolution a central component of both drug development and interpretation of treatment failure.

Pharmacology, adverse effects, and treatment burden

The effectiveness of a targeted drug depends on whether enough active agent reaches the relevant tissue for a sufficient period. Pharmacokinetics describes absorption, distribution, metabolism, and elimination, while pharmacodynamics concerns the relationship between exposure and biological effect. Oral kinase inhibitors may be affected by food, gastric acidity, liver enzymes, and drug transporters. Antibodies have different distribution and clearance properties, including recycling through the neonatal Fc receptor and, for some agents, clearance influenced by target binding. A drug’s dose therefore cannot be inferred simply from the amount of target present.

Anatomical barriers also influence exposure. The blood–brain barrier and active transport systems can limit concentrations of some medicines in the central nervous system. Differences among inhibitors directed at the same protein may produce clinically important differences in intracranial activity. Drug penetration can also vary within a tumor because of abnormal vessels, high interstitial pressure, fibrosis, or regions of poor perfusion. These factors help explain why potent activity in isolated cells does not necessarily predict activity in a patient.

Many adverse effects result from inhibiting a target that has normal physiological functions. EGFR inhibition commonly produces acneiform skin eruptions and diarrhea, reflecting EGFR activity in skin and gastrointestinal tissues. VEGF-pathway inhibition can cause hypertension, proteinuria, bleeding, and impaired wound healing. HER2-directed treatment can impair cardiac function, although risk differs across agents and combinations. Some kinase inhibitors affect cardiac repolarization, arterial health, or ventricular function. These are examples of mechanism-related toxicity, not evidence that targeting has failed at the molecular level.

Other toxicities are specific to a drug, payload, or treatment context. Antibody–drug conjugates can produce marrow suppression, neuropathy, liver injury, or pulmonary toxicity depending on their components. Trastuzumab deruxtecan is associated with interstitial lung disease, which can be serious or fatal. BTK inhibitors differ in their risks of bleeding, atrial fibrillation, and other cardiovascular events. Rapid destruction of sensitive malignant cells can cause tumor lysis syndrome, a particularly important recognized risk with venetoclax in susceptible disease settings. PARP inhibitors commonly cause fatigue and cytopenias and have a recognized association with uncommon myelodysplastic syndrome or acute myeloid leukemia.

Safety assessment consequently includes agent-specific laboratory testing, cardiac evaluation, assessment of interacting medicines, and monitoring during treatment. Dose interruption or modification is incorporated into clinical protocols and product labeling for defined adverse effects. Long-term treatment also brings practical burdens: frequent appointments, daily dosing, cumulative symptoms, and financial costs. Quality of life is therefore distinct from tumor shrinkage. A therapy may provide prolonged disease control while imposing continuing toxicity, making both clinical outcomes and patient-reported outcomes important components of its evaluation.

Clinical evidence, endpoints, and regulatory evaluation

A convincing molecular mechanism is the starting point for development, not proof of clinical effectiveness. Early studies investigate dose, toxicity, exposure, target engagement, and preliminary antitumor activity. Later studies evaluate whether treatment improves outcomes in a defined population. A randomized controlled trial can distinguish the treatment effect from differences in prognosis, patient selection, and supportive care. Randomization remains valuable even when every participant carries the same biomarker, because molecularly selected cancers can still vary substantially in behavior.

Targeted therapy has encouraged several specialized clinical trial designs. A basket trial evaluates a drug or strategy across different cancers sharing a molecular feature. An umbrella trial assigns people with one broad cancer type to different treatments according to their tumor’s alterations. Platform trials can add or remove treatment groups over time. These approaches can improve the efficiency of studying uncommon subgroups, but each creates analytical challenges, including small sample sizes, multiple comparisons, differing natural histories, and uncertainty about whether results can be pooled across tumor types.

Endpoints measure different aspects of benefit. Objective response rate records the proportion of participants meeting predefined criteria for tumor shrinkage; duration of response measures how long that response persists. Progression-free survival measures time to progression or death, while overall survival measures time to death from any cause. In some blood cancers, molecular response or measurable residual disease provides additional information about disease burden. A surrogate endpoint can support earlier assessment, but improvement in a surrogate does not automatically establish longer survival or better quality of life.

Effect size must be interpreted alongside the comparator, follow-up, absolute outcomes, and adverse events. A hazard ratio summarizes relative event rates over time under particular statistical assumptions; it is not the proportion of individuals cured or a direct statement of extra months lived. Overall-survival analysis may be complicated when participants cross over to the experimental treatment or receive effective subsequent therapies. Conversely, prolonged progression-free survival can have clinical importance even when a survival difference is difficult to demonstrate, especially if symptoms and treatment burden are also favorably affected.

Regulatory pathways differ among jurisdictions. In the United States, accelerated approval can rely on endpoints considered reasonably likely to predict clinical benefit, with confirmatory studies required to verify benefit. Such approvals may later be converted, narrowed, or withdrawn. A regulatory indication is therefore specific to a drug, biomarker, cancer setting, and sometimes prior treatment history. Approval of one inhibitor does not validate every drug acting on the same pathway, and activity in a small uncontrolled study does not establish equivalence to an existing standard. Postmarketing safety surveillance and additional trials remain important after initial authorization.

Access, implementation, and continuing research

Delivering targeted therapy requires more than obtaining a drug. Tissue collection, reliable pathology, validated molecular testing, timely reporting, and interpretation all form part of the treatment pathway. A test may be technically available yet arrive too late to influence a decision, or it may detect an alteration for which no locally accessible treatment exists. Implementation therefore depends on the organization and financing of the health system as well as laboratory technology. The gap between finding a molecular abnormality and obtaining a proven matched therapy is especially important when assessing the real-world reach of precision oncology.

Costs extend across testing, medicines, monitoring, management of adverse effects, and travel to specialist services. Oral therapy transfers some treatment activity from clinics to the home but does not eliminate professional supervision or financial burden. Generic versions of small molecules and biosimilars of certain antibodies can change affordability, although their availability and reimbursement vary by jurisdiction. Economic evaluations may use measures such as the quality-adjusted life-year, but their results depend on assumptions about duration of benefit, subsequent treatment, prices, and the health system’s available resources.

Unequal access to molecular testing and trials can contribute to differences in outcomes. Geography, insurance arrangements, laboratory infrastructure, and underrepresentation of some populations in research all affect implementation. Tumor profiling can also uncover findings suggestive of an inherited cancer predisposition. A tumor result alone does not always establish that an alteration is present throughout the body; constitutional testing and genetic counseling address a different question from selecting a tumor-directed drug. Genetic information consequently creates laboratory, consent, and data-governance requirements beyond those of routine drug prescribing.

Research continues to refine what constitutes an actionable dependency. Mutant-selective inhibitors seek to spare the normal form of a protein, potentially widening the therapeutic index. Allosteric inhibitors, covalent inhibitors, protein degraders, improved conjugates, and radiopharmaceuticals explore different ways to reach previously difficult targets. Spatial and single-cell methods examine how neighboring cells and subclonal populations influence response. Computational models can help prioritize hypotheses, but predictions still require experimental and clinical validation.

Another active area is the use of circulating tumor DNA to detect residual disease after apparently curative treatment or to identify emerging resistance before radiological progression. Detection can provide prognostic information, but a test’s ability to predict relapse does not by itself prove that changing treatment on that basis improves outcomes. Trials must establish which interventions, thresholds, and timing produce benefit. Similar uncertainty applies to many proposed drug combinations: deeper pathway suppression may prevent escape, yet overlapping toxicity and effects on normal tissues can make a biologically plausible combination clinically unsuitable.